Asia Pacific Sepsis Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product, Technology, Method, Test Type, Pathogen, and End User

The APAC sepsis diagnostics market is expected to grow from US$ 131.79 million in 2021 to US$ 249.70 million by 2028; it is estimated to grow at a CAGR of 9.6% from 2021 to 2028.

The rising need for rapid diagnostics for sepsis fueled the research activities among key players in recent years.Both the existing players and the start-ups in sepsis diagnostics are well supported financially by government and research organizations.

For instance, in April 2020, Cytovale Inc. announced its partnership with the Biomedical Advanced Research and Development Authority (BARDA) for sepsis diagnosis in patients with respiratory infections, including COVID-19. The research was estimated to stand at US$ 5.9 million, with a contribution of approximately US$ 3.83 million by BARDA. Additionally, in an endeavor to shape the future of sepsis research, the National Institute of General Medical Sciences (NIGMS) intends to use the NIH SBIR/STTR program to support preclinical and clinical sepsis studies to develop improved diagnostic tools and therapies. Diagnostics companies are continuously securing funding to establish rapid sepsis diagnostic tests.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets.This factor is likely to drive the APAC sepsis diagnostics market.

The APAC sepsis diagnostics market is expected to grow at a good CAGR during the forecast period.

APAC Sepsis Diagnostics Market Revenue and Forecast to 2028 (US$ Million )

APAC Sepsis Diagnostics Market Segmentation

The APAC sepsis diagnostics market is segmented based on product, technology, method, test type, pathogen, end user, and country.Based on product, the APAC sepsis diagnostics market is divided into instruments, reagents and assays, blood culture media, and software.

The blood culture media dominated the APAC sepsis diagnostics market in 2021.Based on technology, the APAC sepsis diagnostics market is categorized into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology.

The microbiology segment dominated the APAC sepsis diagnostics market in 2021.Based on method, the APAC sepsis diagnostics market is categorized into automated diagnostics and conventional diagnostics.

The conventional diagnostics segment dominated the APAC sepsis diagnostics market in 2021. Based on test type, the APAC sepsis diagnostics market is categorized into point-of-care tests and laboratory tests. The laboratory tests segment dominated the APAC sepsis diagnostics market in 2021. Based on pathogen, the APAC sepsis diagnostics market is categorized into bacterial sepsis, fungal sepsis, and others. The bacterial sepsis segment dominated the APAC sepsis diagnostics market in 2021. Based on end user, the APAC sepsis diagnostics market is categorized into hospitals, pathology and reference laboratories, and others. The hospitals segment dominated the APAC sepsis diagnostics market in 2021. Based on country, the APAC sepsis diagnostics market is segmented into Australia, China, India, Japan, South Korea, and the Rest of APAC. China dominated the APAC sepsis diagnostics market in 2021.

Key players operating in the APAC sepsis diagnostics market include Abbott; F. HOFFMANN-LA ROCHE LTD.; Immunexpress Inc.; BD; Danaher (Beckman Coulter); Luminex Corporation; THERMO FISHER SCIENTIFIC INC.; bioMerieux SA; and T2 Biosystems, Inc. by Altair.